PARK MEDI WORLD vs Rainbow Children'S Medicare: Share Price, Valuation and Results Compared

PARK MEDI WORLD LIMITED (NSE: PARKHOSPS) and Rainbow Children'S Medicare Limited (NSE: RAINBOW) are both listed in the Hospitals and Healthcare Centers industry. PARK MEDI WORLD has a market capitalisation of ₹9,670 Cr and Rainbow Children'S Medicare ₹12,586 Cr, as of 9 Nov 2026. Their P/E ratios are 34.5 and 45.2 respectively. Return on equity is 13.00% for PARK MEDI WORLD and 17.94% for Rainbow Children'S Medicare.

PARK MEDI WORLD vs Rainbow Children'S Medicare — Key Figures

MetricPARK MEDI WORLDRainbow Children'S Medicare
NSE SymbolPARKHOSPSRAINBOW
BSE Code544645543524
Share Price₹267.40₹1,278.50
Market Cap₹9,670 Cr₹12,586 Cr
P/E Ratio34.545.2
Return on Equity13.00%17.94%
Return on Assets9.66%9.55%
Dividend Yield—0.28%
Beta (1Y)0.930.41
1-Year Price Change—-6.6%
3-Month Price Change-7.5%-16.9%
52-Week Range₹138.10 – ₹305.00₹1,084.00 – ₹1,610.00
Latest QuarterQ1 FY27Q2 FY27
Quarterly Revenue₹476 Cr₹548 Cr
Quarterly Net Profit₹89 Cr₹84 Cr
Net Margin18.6%15.3%
EPS (Basic, Quarter)₹2.05₹8.10
Results Basisconsolidatedconsolidated
HeadquartersGurugram, HaryanaHyderabad, Telangana

The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.

About the Companies

PARK MEDI WORLD LIMITED

Park Medi World Limited operates a network of hospitals. The company provides cardiac sciences, neurosciences - brain and spine, plastic and cosmetic surgery, general and laparoscopic surgery, renal sciences and kidney transplant, bone, orthopaedics, joint replacement and sports medicine, gastroenterology and surgical gastroenterology, cancer care, bone marrow transplant, iMARS / robot-assisted surgery. It also offers bariatric surgery, anaesthesiology, critical care, chest and respiratory diseases, dental care, dermatology, endocrinology, paediatrics, internal medicine and geriatrics, rheumat…

Rainbow Children'S Medicare Limited

Rainbow Children's Medicare Limited operates a multi-specialty paediatric, obstetrics, and gynaecology hospital chain in India. The company offers medical and healthcare services to children and women. It also provides pediatric services under brand Rainbow Children’s Hospital which include newborn and pediatric intensive care; pediatric multi-specialty services; and pediatric quaternary care, such as multi-organ transplantation. In addition, the company offers women care services under Birthright brand that comprise perinatal care services, such as routine and complex obstetric care, multi-di…

Frequently Asked Questions

Which is larger by market cap, PARK MEDI WORLD or Rainbow Children'S Medicare?

Rainbow Children'S Medicare has a market capitalisation of ₹12,586 Cr, against ₹9,670 Cr for PARK MEDI WORLD as of 9 Nov 2026, about 1.3 times the size by market cap.

What is the P/E ratio of PARK MEDI WORLD and Rainbow Children'S Medicare?

PARK MEDI WORLD has a P/E of 34.5 and Rainbow Children'S Medicare a P/E of 45.2 as of 9 Nov 2026.

What is the return on equity of PARK MEDI WORLD and Rainbow Children'S Medicare?

PARK MEDI WORLD has a return on equity of 13.00% and Rainbow Children'S Medicare 17.94%.

What were the latest quarterly results of PARK MEDI WORLD and Rainbow Children'S Medicare?

PARK MEDI WORLD reported revenue of ₹476 Cr and net profit of ₹89 Cr for Q1 FY27. Rainbow Children'S Medicare reported revenue of ₹548 Cr and net profit of ₹84 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.

Which industry are PARK MEDI WORLD and Rainbow Children'S Medicare in?

Both are classified under Health Care Providers and Services > Health Care Facilities > Hospitals and Healthcare Centers on FinBizNet.

Is this comparison a recommendation to buy or sell PARK MEDI WORLD or Rainbow Children'S Medicare?

No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.

More Comparisons

More on FinBizNet

Data as of 9 Nov 2026. Descriptive market data only — not investment advice.